Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1973 3
1975 1
1980 1
1981 1
1984 5
1985 7
1986 7
1987 7
1988 6
1989 11
1990 7
1991 8
1992 11
1993 10
1994 15
1995 26
1996 34
1997 26
1998 19
1999 38
2000 54
2001 43
2002 30
2003 47
2004 60
2005 69
2006 83
2007 77
2008 84
2009 72
2010 91
2011 95
2012 135
2013 144
2014 184
2015 186
2016 180
2017 230
2018 264
2019 291
2020 381
2021 499
2022 301
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

3,411 results
Results by year
Filters applied: . Clear all
Page 1
The JAK/STAT signaling pathway: from bench to clinic.
Hu X, Li J, Fu M, Zhao X, Wang W. Hu X, et al. Among authors: fu m. Signal Transduct Target Ther. 2021 Nov 26;6(1):402. doi: 10.1038/s41392-021-00791-1. Signal Transduct Target Ther. 2021. PMID: 34824210 Free PMC article. Review.
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. Voors AA, et al. Among authors: fu m. Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28. Nat Med. 2022. PMID: 35228754 Free PMC article. Clinical Trial.
FBXL2 counteracts Grp94 to destabilize EGFR and inhibit EGFR-driven NSCLC growth.
Niu M, Xu J, Liu Y, Li Y, He T, Ding L, He Y, Yi Y, Li F, Guo R, Gao Y, Li R, Li L, Fu M, Hu Q, Luo Y, Zhang C, Qin K, Yi J, Yu S, Yang J, Chen H, Wang L, Li Z, Dong B, Qi S, Ouyang L, Zhang Y, Cao Y, Xiao ZJ. Niu M, et al. Among authors: fu m. Nat Commun. 2021 Oct 11;12(1):5919. doi: 10.1038/s41467-021-26222-x. Nat Commun. 2021. PMID: 34635651 Free PMC article.
Disrupting Roquin-1 interaction with Regnase-1 induces autoimmunity and enhances antitumor responses.
Behrens G, Edelmann SL, Raj T, Kronbeck N, Monecke T, Davydova E, Wong EH, Kifinger L, Giesert F, Kirmaier ME, Hohn C, de Jonge LS, Pisfil MG, Fu M, Theurich S, Feske S, Kawakami N, Wurst W, Niessing D, Heissmeyer V. Behrens G, et al. Among authors: fu m. Nat Immunol. 2021 Dec;22(12):1563-1576. doi: 10.1038/s41590-021-01064-3. Epub 2021 Nov 22. Nat Immunol. 2021. PMID: 34811541
Application of Comprehensive Artificial intelligence Retinal Expert (CARE) system: a national real-world evidence study.
Lin D, Xiong J, Liu C, Zhao L, Li Z, Yu S, Wu X, Ge Z, Hu X, Wang B, Fu M, Zhao X, Wang X, Zhu Y, Chen C, Li T, Li Y, Wei W, Zhao M, Li J, Xu F, Ding L, Tan G, Xiang Y, Hu Y, Zhang P, Han Y, Li JO, Wei L, Zhu P, Liu Y, Chen W, Ting DSW, Wong TY, Chen Y, Lin H. Lin D, et al. Among authors: fu m. Lancet Digit Health. 2021 Aug;3(8):e486-e495. doi: 10.1016/S2589-7500(21)00086-8. Lancet Digit Health. 2021. PMID: 34325853 Free article.
3,411 results